Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Set on La Gorce Island, a Miami Beach residence listed for $88 million—dubbed Okto—spans nearly 16,000 square feet with 260 ...

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

The trial of three men accused in the theft or sale of an 18-carat gold toilet that was a pricey piece of satirical art is ...

Guggenheim reiterated their sell rating on shares of Tesla (NASDAQ:TSLA – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. A number of other analysts have also recently ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

The $6.1 million artwork by Maurizio Cattelan was stolen from the Blenheim Palace in England in September 2019.

As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price ...

In Miami Beach, Fla., a waterfront estate asking $88 million has elements inspired by Manhattan’s Guggenheim Museum.

LG and the Guggenheim New York proudly announce Ayoung Kim as the 2025 LG Guggenheim Award recipient. Kim is the third artist to be recognized as part of the LG Guggenheim Art and Technology ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...